臨床研究等提出・公開システム

BSJ017W versus NOAC for Embolic Protection in the Management of Patients with Non-Valvular Atrial Fibrillation (CHAMPION-AF Clinical Trial)

CHAMPION-AF Clinical Trial

Kawahara Kazuo

Boston Scientific Japan K.K.

4-10-2 Nakano, Nakano-ku, Tokyo

JapanClinicalTrials@bsci.com

Ito Naoaki

Boston Scientific Japan K.K.

4-10-2 Nakano, Nakano-ku, Tokyo

+81-3-6853-7500

JapanClinicalTrials@bsci.com

Not Recruiting

Sept. 16, 2021

Interventional

randomized controlled trial

open(masking not used)

active control

parallel assignment

prevention purpose

- The subject is of legal age to participate in the study per the laws of their respective geography
- The subject has documented non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve)
- The subject has a calculated CHA2DS2-VASc score of 2 or greater for men and 3 or greater for women
- The subject is deemed to be suitable for the protocol defined pharmacologic regimens in both the test and control arms
- The subject or legal representative is able to understand and willing to provide written informed consent to participate in the trial
- The subject is able and willing to return for required follow-up visits and examinations

- Subjects who are currently enrolled in another investigational study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments
- The subject requires long-term anticoagulation therapy for reasons other than AF-related stroke risk reduction, for example due to an underlying hypercoagulable state (i.e., even if the device is implanted, the subjects would not be eligible to discontinue OAC due to other medical conditions requiring chronic OAC therapy)
- The subject is contraindicated or allergic to oral anticoagulation medication and/or aspirin
- The subject is indicated for chronic P2Y12 platelet inhibitor therapy
- The subject had or is planning to have any cardiac or non-cardiac intervention or surgical procedure within 30 days prior to or 60 days after implant (including, but not limited to: cardioversion, percutaneous coronary intervention (PCI), cardiac ablation, cataract surgery, etc.)
- The subject had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 30 days prior to enrollment
- The subject had a prior major bleeding event per ISTH definition within the 30 days prior to randomization. Lack of resolution of related clinical sequelae or planned and pending interventions to resolve bleeding/bleeding source, are a further exclusion regardless of timing of the bleeding event
- The subject has an active bleed
- The subject has a reversible cause of AF or transient AF
- The subject is absent of a LAA or the LAA is surgically ligated
- The subject has had a myocardial infarction (MI) documented in the clinical record as either a non-ST elevation MI (NSTEMI) or as an ST-elevation MI (STEMI), with or without intervention, within 30 days prior to enrollment
- The subject has a history of atrial septal repair or has an ASD/PFO device
- The subject has an implanted mechanical valve prosthesis in any position
- The subject has a known contraindication to percutaneous catheterization procedure
- The subject has a known contraindication to TEE
- The subject has a cardiac tumor
- The subject has signs/symptoms of acute or chronic pericarditis.
- The subject has an active infection
- There is evidence of tamponade physiology
- The subject has New York Heart Association Class IV Congestive Heart Failure at the time of enrollment
- The subject is of childbearing potential and is, or plans to become, pregnant during the time of the study (method of assessment upon study physician's discretion)
- The subject has a documented life expectancy of less than 3 years

Transthoracic Echo Exclusion Criteria
- The subject has LVEF < 30%
- The subject has an existing pericardial effusion with a circumferential echo-free space > 5mm
- The subject has a high-risk patent foramen ovale (PFO) with an atrial septal aneurysm excursion > 15mm or length > 15mm
- The subject has significant mitral valve stenosis (i.e., MV area < 1.5 cm^2)

Both

Non-valvular atrial fibrillation

The device group has intervention with left atrial appendage closure device and the control group has NOAC treatment.

1. BSJ017W is non-inferior (NI) for the occurrence of stroke, cardiovascular death, and systemic embolism at 36-months.
2. BSJ017W is superior for non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding) at 36-months.
3. BSJ017W is non-inferior (NI) for the occurrence of ischemic stroke and systemic embolism at 60 months.

+81-93-511-2000

Aug. 23, 2021

Yes

Please refer to the following to request study data. http://www.bostonscientific.com/content/gwc/en-US/data-sharing-requests.html

USA/Belgium/Italy/Denmark/Spain/Poland/Canada/France/Germany/Israel/Saudi Arabia/Netherlands/UK/Australia/Switzerland